| 1.33 -0.01 (-0.75%) | 01-23 09:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.93  |
1-year : | 2.2 |
| Resists | First : | 1.65 |
Second : | 1.88 |
| Pivot price | 1.46 |
|||
| Supports | First : | 1.28 | Second : | 1.07 |
| MAs | MA(5) : | 1.35 |
MA(20) : | 1.47 |
| MA(100) : | 2.08 |
MA(250) : | 2.85 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 11.9 |
D(3) : | 13.1 |
| RSI | RSI(14): 29.1 | |||
| 52-week | High : | 8.93 | Low : | 1.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MDCX ] has closed above bottom band by 18.3%. Bollinger Bands are 27.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.48 - 1.49 | 1.49 - 1.5 |
| Low: | 1.28 - 1.29 | 1.29 - 1.3 |
| Close: | 1.33 - 1.34 | 1.34 - 1.35 |
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.
Mon, 12 Jan 2026
Single hormone shot kept levels low for weeks with no short-term bone loss - Stock Titan
Tue, 30 Dec 2025
Medicus Pharma Signs Equity Distribution Agreement With Maxim Group and Yorkville Securities - TradingView — Track All Markets
Mon, 29 Dec 2025
Medicus Pharma launches at-the-market equity offering program - MSN
Mon, 22 Dec 2025
AI data crunching aims to speed testing of new prostate cancer drug - Stock Titan
Tue, 25 Nov 2025
Maxim Group Reaffirms Buy on Medicus Pharma Ltd (MDCX) With $20 Target - Yahoo Finance
Fri, 14 Nov 2025
Medicus Pharma (NASDAQ:MDCX) receives UK approvals to expand Phase 2 BCC trial - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 1.629e+007 (%) |
| Held by Institutions | 28.9 (%) |
| Shares Short | 493 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -170.7 % |
| Return on Equity (ttm) | -2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 57.95 |
| Dividend | 0 |
| Forward Dividend | 803760 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|